logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Bluebird Bio, Inc.


USPTO Granted Patents = 35

% Expired Patents = 2.9



Forward Citations = 315

Loading Chart...
Loading Chart...

26 inventors (with patents filed for the assignee):

goldMedal Kevin Friedman (8 out of 21 patents)

silverMedal Richard Morgan (7 out of 14 patents)

bronzeMedal Jordan Jarjour (6 out of 24 patents)

4.  Karen Westerman (6 out of 10 patents)

5.  Olivier Negre (5 out of 5 patents)

6.  Philippe Louis Leboulch (5 out of 5 patents)

7.  Robert Pawliuk (5 out of 5 patents)

8.  Garrett Collins Heffner (4 out of 4 patents)

9.  Abraham Isaac Bassan (4 out of 4 patents)

10.  Alexander Astrakhan (4 out of 10 patents)

11.  Michael Certo (4 out of 6 patents)

12.  Gabor Veres (4 out of 6 patents)

13.  Maria Joann Denaro (3 out of 3 patents)

14.  Mitchell Howard Finer (3 out of 3 patents)

15.  Julian Down (3 out of 3 patents)


Core Competencies:
Chimeric Antigen Receptors
Gene Therapy
Viral Transduction
Retroviral Vectors
Hemoglobinopathies
Interleukin Receptors
Endonuclease Variants
T Cell Compositions
Signaling Proteins
Adrenoleukodystrophy
Adrenomyeloneuropathy
Enhancer Compositions

35 patents:

1. 12760099 - MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF (2026-10-13),
2. 12686711 - DARIC INTERLEUKIN RECEPTORS (2026-07-21),
3. 12234476 - VCN enhancer compositions and methods of using the same (2025-02-25),
4. 12234296 - Sickled beta globin antibodies (2025-02-25),
5. 11834668 - Compounds for improved viral transduction (2023-12-05),
6. 11701435 - Therapeutic retroviral vectors for gene therapy (2023-07-18),
7. 11535681 - Sickled beta globin antibodies (2022-12-27),
8. 11326183 - VCN enhancer compositions and methods of using the same (2022-05-10),
9. 11261441 - Vectors and compositions for treating hemoglobinopathies (2022-03-01),
10. 11020466 - BCMA chimeric antigen receptors (2021-06-01),
11. 10927367 - CBLB endonuclease variants, compositions, and methods of use (2021-02-23),
12. 10907177 - Compounds for improved viral transduction (2021-02-02),
13. 10793843 - CBLB endonuclease variants, compositions, and methods of use (2020-10-06),
14. 10774343 - MND promoter chimeric antigen receptors (2020-09-15),
15. 10646558 - BCMA chimeric antigen receptors (2020-05-12),
Company Overview
Bluebird Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in developing innovative gene therapies for severe genetic diseases and cancer. The organization focuses on harnessing the power of genetic engineering to create transformative treatments that address the underlying causes of these conditions. With a commitment to advancing the field of gene therapy, Bluebird Bio aims to improve patient outcomes and enhance the quality of life for individuals affected by rare and complex diseases.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Bluebird Bio, Inc. USPTO Patent Assignee Logo
35 Patents

#83 in Cambridge, MA

#583 in Massachusetts

#9,749 in US

#19,168 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Bluebird Bio, Inc.

Forward Citations = 315

26 inventors:

goldMedal Kevin Friedman (8 out of 21 patents)

silverMedal Richard Morgan (7 out of 14 patents)

bronzeMedal Jordan Jarjour (6 out of 24 patents)

4.  Karen Westerman (6 out of 10 patents)

5.  Olivier Negre (5 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Bluebird Bio, Inc.. Retrieved from https://idiyas.com/company/bluebird-bio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…